Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic...

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Chronic heart failure (HF) presents a significant global health challenge with substantial economic and psychosocial burdens.
• Despite evidence-based guidelines, HF management faces challenges in reducing hospitalization, readmission, morbidity, and mortality rates.

Purpose of the Study:

• To evaluate the synergistic effect of baseline HF drug therapy (BDT) and add-on HF drug therapy (ADT) on survival and hospitalization-free event rates.
• To analyze the contribution of BDT and initial HF drug therapy (IDT) within current chronic HF clinical practice guidelines.

Main Methods:

• A comprehensive review of references from major chronic HF clinical practice guidelines (AHA/ACC, HFSA, ESC) published between 2005 and 2013.
• Comparison of cited recommendations and outcomes with respective guidelines and international standards.

Main Results:

• Baseline HF drug therapy (BDT) demonstrated survival rates of 46%-89% and hospitalization-free rates of 47.1%-85.3%.
• Initial HF drug therapy (IDT) showed survival rates of 61%-92.8% and hospitalization-free rates of 61.8%-90%.
• Add-on HF drug therapy (ADT) contributed an additional 0.4%-15% to survival and 4.6%-14.7% to hospitalization-free rates, indicating a synergistic effect.

Conclusions:

• Baseline HF drug therapy (BDT) significantly contributes to improved survival and reduced hospitalizations in chronic heart failure.
• The initial HF drug therapy (IDT) recommended in guidelines appears to have synergistic effects when combined with BDT, essentially functioning as add-on therapy (ADT).
• Polypharmacy in HF treatment, combining BDT and ADT, results in a significant synergistic benefit.